SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-130432"
 

Search: onr:"swepub:oai:DiVA.org:liu-130432" > Nodal involvement i...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Loftås, PerLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken ViN (author)

Nodal involvement in luminal complete response after neoadjuvant treatment for rectal cancer

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • ELSEVIER SCI LTD,2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-130432
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-130432URI
  • https://doi.org/10.1016/j.ejso.2016.03.013DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Pathological complete response (pCR) after neoadjuvant therapy in rectal cancer is correlated with improved survival. There is limited knowledge on the incidence of pCR at a national level with uniform guidelines. The aim of this prospective register-based study was to investigate the incidence and outcome of pCR in relation to neoadjuvant therapy in a national cohort. Method: All patients abdominally operated for rectal cancer between 2007 and 2012 (n = 7885) were selected from The Swedish Colorectal Cancer Register. Twenty-six per cent (n = 2063) had neoadjuvant therapy with either long or short course radiotherapy with amp;gt;4 weeks delay with the potential to achieve pCR. The primary endpoints were pCR and survival in relation to neoadjuvant therapy. Results: Complete eradication of the luminal tumor, ypTO was found in 161 patients (8%). In 83% of the ypTO the regional lymph nodes were tumor negative (ypTONO), 12% had 1-3 positive lymph nodes (ypTON1) and 4% had more than three positive lymph nodes (ypTON2). There was significantly greater survival with ypTO compared to ypT+ (hazard ratio 0.38 (C.I 0.25-0.58)) and survival was significantly greater in patients with ypTONO compared to ypT0N1-2 (hazard ratio 0.36 (C.I 0.15-0.86)). In ypTO, cT3-4 tumors had the greater risk of node-positivity. The added use of chemotherapy resulted in 10% ypTO compared to 5.1% in the group without chemotherapy (p amp;lt; 0.00004). Conclusion: Luminal pathological complete response occurred in 8%, 16% of them had tumor positive nodes. The survival benefit of luminal complete response is dependent upon nodal involvement status. (C) 2016 Elsevier Ltd. All rights reserved.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Arbman, GunnarLinköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Region Östergötland, Kirurgiska kliniken ViN(Swepub:liu)gunar63 (author)
  • Fomichov Casaballe, VictoriaLinköpings universitet,Institutionen för medicin och hälsa,Medicinska fakulteten,Region Östergötland, Regionalt cancercentrum(Swepub:liu)vicfo67 (author)
  • Hallböök, OlofLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US(Swepub:liu)oloha72 (author)
  • Linköpings universitetAvdelningen för kliniska vetenskaper (creator_code:org_t)

Related titles

  • In:European Journal of Surgical Oncology: ELSEVIER SCI LTD42:6, s. 801-8070748-79831532-2157

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Loftås, Per
Arbman, Gunnar
Fomichov Casabal ...
Hallböök, Olof
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Cancer and Oncol ...
Articles in the publication
European Journal ...
By the university
Linköping University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view